Rifampin drastically reduces plasma concentrations and effects of oral midazolam

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 1, 1996, Pages 7-13

  Backman, Janne T ^a   Olkkola, Klaus T ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

MIDAZOLAM; PLACEBO; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTIBIOTICS, ANTITUBERCULAR; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; ENZYME INDUCTION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDAZOLAM; MIXED FUNCTION OXYGENASES; PSYCHOMOTOR PERFORMANCE; REFERENCE VALUES; RIFAMPIN;

EID: 0030068752     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90018-1     Document Type: Article

References (26)

1. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. CLIN PHARMACOL THER 1981;30:653-61.
2. Kronbach T, Mathys D, Umeno M, Gonzales FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
3. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. CLIN PHARMACOL THER 1994;55:481-5.
4. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. CLIN PHARMACOL THER 1993;53:298-305.
5. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen PJ. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994;37:221-5.
6. Gascon MP, Dayer P. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 1991;41:573-8.
7. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
8. Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporin A; IV: purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989; 17:197-207.
9. Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18:595-606.
10. Ged C, Rouillon JM, Pichard L, et al. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989;28:373-87.
11. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989;83:688-97.
12. Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992;22:47-65.
13. DeKroon IFI, Langendijk PNJ, De Goede PNFC. Simultaneous determination of midazolam and its three hydroxy metabolites in human plasma by electron-capture gas chromatography without derivatization. J Chromatogr 1989;491:107-16.
14. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
15. Stone BI. Pencil and paper tests - sensitivity to psychotropic drugs. Br J Clin Pharmacol 1984;18:15S-20S.
16. Smith JM, Misiak H. Critical flicker frequency (CFF) and psychotropic drugs in normal human subjects - a review. Psychopharmacology 1976;47:175-82.
17. Hannington-Kiff JG. Measurements of recovery from outpatient general anaesthesia with a simple ocular test. Br Med J 1970;3:132-5.
18. Bond A, Lader MH. The use of visual analogue scales in rating subjective feelings. Br J Med Psychol 1974; 47:211-8.
19. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. CLIN PHARMACOL THER 1994;56:601-7.
20. Wilkinson L, Hill M, Welna JP, Birkenbeuel GK. Systat for windows: statistics; version 5 edition. Evanston, Illinois: Systat, 1992.
21. Dollery C, ed. Therapeutic drugs; vol. 2. Edinburgh, Great Britain: Churchill Livingstone, 1991:M195-9.
22. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994;26:144-60.
23. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe; I: in vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-56.
24. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe; II: characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271:557-66.
25. Lown KS, Thummel KE, Benedict PE et al. The erythromycin breath test predicts the clearance of midazolam. CLIN PHARMACOL THER 1995;57:16-24.
26. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;47:1643-53.